Key Highlights

  • 6.43% is the indicated pre-market move for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) on November 17, 2026, taking the indicated price to USD 7.95 from a calculated prior close of USD 7.47.
  • 80 events were reached in the pivotal REGAL Phase 3 trial in October 2026, and management expects topline primary endpoint results of galinpepimut-S in AML patients in November 2026.
  • 134.7 million is the USD cash and cash equivalents balance reported at September 30, 2026, up from USD 71.8 million at December 31, 2025, against a third quarter net loss of USD 10.1 million.
  • 1.62 billion is the calculated USD market Capitalization at the indicated price, based on 203,527,833 shares outstanding at September 30, 2026, up from 153,103,459 shares at December 31, 2025.

What Moved SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) in Pre-Market Trading on November 17, 2026 (+USD 0.48, +6.43%)

The indicated pre-market price on November 17, 2026 is USD 7.95, a pre-market move of +6.43%. On a calculated basis, the prior close was USD 7.47 (price divided by 1.0643) and the USD move is +USD 0.48 (price minus prior close). Market capitalization is calculated at about USD 1.62 billion (203,527,833 shares times USD 7.95). No pre-market Volume figures were found in published coverage. The company is a clinical-stage biopharmaceutical group developing AML therapies, led by galinpepimut-S, known as GPS, and tambiciclib, known as SLS009.

The Rationale: Pending REGAL Phase 3 Topline Results for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

The likely driver is anticipation of the REGAL readout. In October 2026 the company announced the pre-specified 80th event in the Phase 3 trial of GPS in AML patients in second complete remission after salvage therapy. The trial now moves through database lock, blinded data review, statistical analysis and unblinding. Chief Executive Angelos Stergiou said the company expects to announce topline primary endpoint results this month and that GPS could be a transformative new immunotherapy if successful. Separately, SLS009 data in relapsed or refractory AML will be presented at the ASH meeting on December 12 to 15, 2026, showing a 54% overall response rate in monocytic AML and 57% in TP53-mutated AML, with median overall survival of 5.8 and 8.8 months.

Valuation, Liquidity and Risks for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

Third quarter Research and Development expense was USD 7.0 million versus USD 4.2 million, and general and administrative expense was USD 4.3 million versus USD 2.9 million. Net loss was USD 10.1 million, or USD 0.05 per share, compared with USD 6.8 million, or USD 0.06 per share, a year earlier. Nine month net loss was USD 28.1 million versus USD 19.2 million. The share count rose by a calculated 50.4 million shares in 2026, so dilution is a factor. The company has no product revenue, and a Phase 3 readout is a binary event that can move the shares sharply in either direction. A negative or delayed result could weigh heavily, and pre-market liquidity is thin.

Where Things Stand

SELLAS (NASDAQ:SLS) is indicated at USD 7.95 in pre-market trading on November 17, 2026, up +6.43% from a calculated prior close of USD 7.47. The setup is dominated by the pending REGAL topline result, which management expects in November 2026 after the 80th event was reached in October. Cash of USD 134.7 million, a nine month net loss of USD 28.1 million and a calculated market capitalization near USD 1.62 billion frame the financial picture. A first line AML Phase 2 study of SLS009 has enrolled 40 of 80 targeted patients, with preliminary topline data expected in the fourth quarter of 2026.